aTYR PHARMA INC — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
aTYR Pharma implemented a 40-for-1 reverse stock split of its common stock, effective October 28, 2026. The amendment to the certificate of incorporation reduces authorized common shares from 340 million to an effective 8.5 million post-split (340M ÷ 40), with fractional shares rounded up to whole shares on a per-holder basis. No financing, asset sale, or operational change accompanies this corporate action.
Why this rating
Reverse split is routine capital structure housekeeping, common for distressed or low-priced stocks. No equity raised, no dilution eliminated, no operational change. Neutral for business trajectory relative to $464M market cap.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.